C4 Therapeutics, Inc.
NASDAQ:CCCC
1.54 (USD) • At close April 25, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Omzet
| 35.584 | 20.756 | 31.096 | 45.785 | 33.195 | 21.381 | 19.364 |
| Kosten van de omzet
| 0 | 117.706 | 7.572 | 2.907 | 77.468 | 47.664 | 28.592 |
| Brutowinst
| 35.584 | -96.95 | 23.524 | 42.878 | -44.273 | -26.283 | -9.228 |
| Brutowinstmarge
| 1 | -4.671 | 0.756 | 0.937 | -1.334 | -1.229 | -0.477 |
| Onderzoek- en ontwikkelingskosten
| 110.637 | 117.706 | 117.841 | 94.665 | 78.44 | 48.059 | 28.592 |
| Algemene en administratieve kosten
| 42.124 | 42.081 | 42.789 | 33.254 | 15.204 | 8.774 | 7.161 |
| Verkoop- en marketingkosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 42.124 | 42.081 | 42.789 | 33.254 | 15.204 | 8.774 | 7.161 |
| Overige kosten
| 2.437 | 0 | 0 | 0 | 0 | 0.325 | -0.007 |
| Bedrijfskosten
| 155.198 | 159.787 | 160.63 | 127.919 | 93.644 | 56.833 | 35.753 |
| Bedrijfsresultaat
| -119.614 | -139.031 | -129.534 | -82.134 | -60.449 | -35.452 | -16.389 |
| Bedrijfsresultaat ratio
| -3.361 | -6.698 | -4.166 | -1.794 | -1.821 | -1.658 | -0.846 |
| Totaal overige inkomsten en kosten netto
| 14.429 | 7.818 | 1.359 | -1.758 | -6.512 | 2.157 | 0.678 |
| Inkomen voor belasting
| -105.185 | -131.213 | -128.175 | -83.892 | -66.961 | -33.295 | -15.711 |
| Inkomen voor belasting ratio
| -2.956 | -6.322 | -4.122 | -1.832 | -2.017 | -1.557 | -0.811 |
| Belastingkosten
| 0.131 | 1.28 | -1.676 | 2.145 | -0.626 | 0.804 | 0.678 |
| Nettowinst
| -105.316 | -132.493 | -126.499 | -86.037 | -66.335 | -34.099 | -15.711 |
| Nettowinstmarge
| -2.96 | -6.383 | -4.068 | -1.879 | -1.998 | -1.595 | -0.811 |
| WPA (Winst Per Aandeel)
| -1.52 | -2.67 | -2.59 | -1.87 | -1.54 | -0.79 | -1.06 |
| Verwaterde WPA
| -1.52 | -2.67 | -2.59 | -1.87 | -1.54 | -0.79 | -1.06 |
| EBITDA
| -103.367 | -122.103 | -124.283 | -78.84 | -62.891 | -30.556 | -15.116 |
| EBITDA ratio
| -2.905 | -5.883 | -3.997 | -1.722 | -1.895 | -1.429 | -0.781 |